NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 201 filers reported holding NEVRO CORP in Q1 2022. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,779,124 | -20.0% | 1,133,149 | +5.8% | 0.02% | -17.9% |
| Q2 2023 | $27,224,286 | -6.2% | 1,070,979 | +33.4% | 0.03% | -9.7% |
| Q1 2023 | $29,013,809 | +9.6% | 802,595 | +20.1% | 0.03% | +6.9% |
| Q4 2022 | $26,464,641 | +65.5% | 668,299 | +94.7% | 0.03% | +52.6% |
| Q3 2022 | $15,994,000 | +0.7% | 343,209 | -5.3% | 0.02% | +5.6% |
| Q2 2022 | $15,880,000 | -45.1% | 362,291 | -9.4% | 0.02% | -33.3% |
| Q1 2022 | $28,908,000 | +28.8% | 399,669 | +44.4% | 0.03% | +42.1% |
| Q4 2021 | $22,438,000 | -55.2% | 276,777 | -35.7% | 0.02% | -57.8% |
| Q3 2021 | $50,100,000 | -50.0% | 430,482 | -28.7% | 0.04% | -47.7% |
| Q2 2021 | $100,137,000 | -5.8% | 603,999 | -20.7% | 0.09% | -16.5% |
| Q1 2021 | $106,307,000 | -44.1% | 762,057 | -30.7% | 0.10% | -39.4% |
| Q4 2020 | $190,315,000 | +7.6% | 1,099,450 | -13.4% | 0.17% | -6.1% |
| Q3 2020 | $176,866,000 | +16.2% | 1,269,677 | -0.4% | 0.18% | 0.0% |
| Q2 2020 | $152,223,000 | +1.0% | 1,274,154 | -15.5% | 0.18% | -23.0% |
| Q1 2020 | $150,752,000 | -33.6% | 1,507,814 | -22.0% | 0.24% | -9.6% |
| Q4 2019 | $227,148,000 | +25.6% | 1,932,518 | -8.2% | 0.26% | +16.6% |
| Q3 2019 | $180,915,000 | +35.0% | 2,104,394 | +1.8% | 0.22% | +33.5% |
| Q2 2019 | $134,029,000 | +15.9% | 2,067,400 | +11.7% | 0.17% | +12.1% |
| Q1 2019 | $115,689,000 | +126.0% | 1,850,720 | +40.6% | 0.15% | +109.9% |
| Q4 2018 | $51,183,000 | +121.8% | 1,316,090 | +225.2% | 0.07% | +153.6% |
| Q3 2018 | $23,071,000 | +546.4% | 404,758 | +805.6% | 0.03% | +460.0% |
| Q2 2018 | $3,569,000 | +339.0% | 44,693 | +376.9% | 0.01% | +400.0% |
| Q1 2018 | $813,000 | +135.7% | 9,372 | +87.4% | 0.00% | – |
| Q4 2017 | $345,000 | +36.9% | 5,000 | +85.9% | 0.00% | – |
| Q1 2017 | $252,000 | -71.2% | 2,689 | -68.0% | 0.00% | -100.0% |
| Q3 2016 | $876,000 | +331.5% | 8,392 | +133.1% | 0.00% | – |
| Q1 2016 | $203,000 | -24.8% | 3,600 | -10.0% | 0.00% | – |
| Q4 2015 | $270,000 | -58.4% | 4,000 | -71.4% | 0.00% | -100.0% |
| Q3 2015 | $649,000 | -0.3% | 13,985 | +15.5% | 0.00% | 0.0% |
| Q2 2015 | $651,000 | – | 12,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |